2. UroToday Home
  3. Video Lectures

Advanced Kidney Cancer

A Phase II Trial of VEGFR-TKI Plus PD-1 Inhibitor in Non-Clear Cell Renal Carcinoma - Jiwei Huang
KIM-1 Biomarker Analysis in the CAN-I Trial for Non-Clear Cell RCC - Wenxin Xu
LITESPARK-024: Belzutifan Plus Palbociclib in Advanced Clear Cell RCC - David McDermott
CYTOSHRINK: Evaluating SBRT to the Primary Tumor in De Novo Advanced RCC - Aly-Khan Lalani
Phase I Trial Explores Formulation of CBM588 Probiotic in Advanced RCC - Miguel Zugman
K-COMPASS Study Investigates ctDNA and KIM-1 in Oligometastatic Kidney Cancer - Chad Tang
KIM-1 Biomarker Evaluated for Association with Outcomes in Advanced RCC Treatment - Wenxin Xu
KEYMAKER-U03 Substudy Compares Four Combinations to Standard Therapy - Cristina Suárez
COSMIC-313 Correlative Analysis Links Specific T-Cell Subset to Improved PFS with Immunotherapy - Berkay Simsek
LenCabo Phase II Trial Investigates Lenvatinib-Everolimus vs Cabozantinib in Relapsed Kidney Cancer - Andrew Hahn
Phase Ib/II Trial Combines Ciforadenant with Ipilimumab and Nivolumab in Frontline Kidney Cancer - Kathryn Beckermann
Feasibility of Using an RNA-Seq Biomarker to Assign Therapy in the OPTIC RCC Trial - Pedro Barata
KIM-1 Biomarker Data from Adjuvant Immunotherapy Trials in Renal Cell Carcinoma - Wenxin Xu
Validation Study of the GRANT Score for Papillary Renal Cell Carcinoma - Michele Maffezzoli
ODYSSEY Study Reveals Real-World Quality of Life in Metastatic Kidney Cancer Patients - Michael Harrison & Benjamin Maughan
CheckMate 214 Final Overall Survival Data: Long-Term Survival Benefits of Ipi/Nivo in Kidney Cancer - Michael Serzan
AUA 2025 Highlights: Advances in Advanced Kidney Cancer - Kelvin Moses
Belzutifan Demonstrates Durable Activity in VHL Disease Tumors - Vivek Narayan
CONTACT-03 Subset Analysis: Similar Cabozantinib Response Across IO Pretreatment Types - Cristina Suárez
PDIGREE Trial Tests Adaptive Immunotherapy Approach for Metastatic Kidney Cancer - Tian Zhang
Triplet Therapy in Kidney Cancer: Insights from COSMIC-313 and the Path Forward - Laurence Albiges
CALYPSO Trial: Savolitinib and Durvalumab in Advanced Papillary Renal Cancer - Francesca Jackson-Spence
KEYMAKER-U03 Trial: Combinatorial Therapies for IO-Refractory Kidney Cancer - Kathryn Beckermann
Combining Radioligand Therapy with Cabozantinib and Nivolumab in Advanced Clear Cell RCC - Eric Jonasch
Outcomes with Novel Combinations in Non-Clear Cell RCC: ORACLE Study - Deepak Kilari
Microbiome Manipulation in the Treatment of Kidney Cancer - Monty Pal
Research Maps Renal Cancer Transcription Signatures - Pedro Barata
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
CheckMate 67T: Subcutaneous Nivolumab Non-Inferior to Intravenous in Advanced RCC - Laurence Albiges
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini
Oligometastatic vs Oligoprogressive RCC Treatment Strategies - Chad Tang
Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran
Glycoproteomics in Kidney Cancer: CheckMate 9ER Biomarker Analysis - David Braun
CaboPoint Trial: Cabozantinib in Second-Line RCC Treatment - Laurence Albiges
Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in TACITO-II Trial - Chiara Ciccarese
HIF-2 Alpha Inhibitor NKT2152 Shows Impact in Renal Cell Carcinoma - Eric Jonasch
TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri
Prognostic Significance of Absolute Lymphocyte Count in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Combination Immunotherapies - Database Consortium - Beyond the Abstract
Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia
Advancements in Cutting-Edge SABR Therapy for Oligometastatic Kidney Cancer - Shankar Siva
CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George
CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir
The Role of Nephrectomy with Immunotherapy in Metastatic Renal Cell Carcinoma - Dimitrios Makrakis
Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon
Bispecific Antibody Inhibiting PD-1 and CTLA-4 Demonstrates Effectiveness Against Advanced Kidney Cancer in Early Study - Martin Voss
Targeted Kidney Cancer Therapy Sparks Hope For Tough-To-Treat Patients - Dan George
The LITESPARK-013 Trial and Belzutifan's Optimal Dose for Treating Metastatic Renal Cell Carcinoma - Neeraj Agarwal
A Conversation on AXL Inhibition in Advanced RCC: Promising Results from a Phase I/IIb Trial - Kathryn Beckermann
Breaking Down Genomic Data: An In-depth Look at Ancestry and Tumor Biology in Kidney Cancer - Ritesh Kotecha
KEYNOTE-B61 Study Reveals Promising Results of Lenvatinib + Pembrolizumab Combo in Non-Clear Cell RCC - Chung-Han Lee
Exploring the Link between Gut Microbiome and Immunotherapy Response in Metastatic Renal Cell Carcinoma - Nazli Dizman
Exploring Cytoreductive Nephrectomy in Metastatic Sarcomatoid or Rhabdoid RCC - Andrew Hahn
Interpreting the Outcomes of a Non-Inferiority Phase II Trial: Comparing Lenvatinib Dosages and Their Impact on the Quality of Life in Renal Cell Carcinoma Patients - Cristiane Bergerot
Impact of Subsequent Therapies in Patients with aRCC Receiving Lenvatinib plus Pembrolizumab or Sunitinib in the CLEAR Study - Martin Voss
A Conversation on Changing Trends in Advanced RCC Treatment: An Analysis of Real-World Data - Neil Shah
Artificial Intelligence Modelling to Predict the Risk of Cardiotoxicity Among Renal Cell Carcinoma Patients - Hesham Yasin
Long-Term Progression Free Survival from TIVO-3: Tivozanib vs Sorafenib in Relapsed/refractory Advanced RCC - Michael Atkins
Efficacy of Lenvatinib + Pembrolizumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma in the CLEAR Trial - Camillo Porta
Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma - Pedro C. Barata
Maturation of Overall Survival in TIVO-3 with Long-Term Follow-Up - Kathryn Beckermann
Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Localized Advanced Non-Metastatic ccRCC - Mehmet Asim Bilen
The SAMURAI Study's Role in Evolving Radiation Therapy for Kidney Cancer - Rana McKay & William Hall
Progression-Free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-Line Immunotherapy Combinations - Kelly Fitzgerald
From Trial to Treatment: Exploring the Lasting Impact of KEYNOTE-426 in Kidney Cancer - Brian Rini
Efficacy over Cost: Unpacking Kidney Cancer Patients' Therapy Selection Priorities - Dena Battle
Deciphering Immunotherapy Responses in Advanced RCC: A Deep Dive into the HCRN Study - Nourhan El Ahmar
Treatment of Recurrent Metastatic Renal Cell Carcinoma After Adjuvant Immunotherapy - Benjamin Berger & Matthew Labriola
Unraveling the Efficacy of PD-1/PDL-1 Re-challenge in Kidney Cancer: CONTACT-03 Study - Toni K. Choueiri
COSMIC-313: Investigating Progression-Free Survival Benefits in Renal Cancer Therapy - Toni K. Choueiri
Combining Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma, Exploring Novel Therapy Options - Toni Choueiri
Comparing the Cost-Effectiveness of Immunotherapy-Based Regimens and Sunitinib in Treating Metastatic Renal Cell Carcinoma from a Public Payer Perspective - Manish Kohli
Overall Survival and Efficacy Results of Second-line Treatment for Patients With Metastatic Clear Cell Renal Cell Carcinoma, BIONIKK Trial -Yann Vano
3-Year Follow-up CheckMate 9ER Trial: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma - Mauricio Burotto
CaboPoint Study: Cabozantinib After Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma - Laurence Albiges
Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Extended Follow-up Results of Cohort 10 of the COSMIC-021 Study - Bradley McGregor
The Evolving Field of Kidney Cancer Treatment: The COSMIC-313 Trial and Beyond - Thomas Powles
HCRN GU 16-260, Nivolumab and Salvage Nivolumab+Ipilimumab in Patients with Advanced Renal Cell Carcinoma Cohort A, Treatment-Free Survival Outcomes - Michael Atkins
Promising Depth of Response Data in Renal Cell Carcinoma: Insights from CheckMate 9ER Trial - Cristina Suárez
BIONIKK Trial: Pioneering Biomarker-Driven Therapy for Advanced Clear Cell RCC - Yann-Alexandre Vano
The CLEAR Study: Lenvatinib + Pembro vs Sunitinib in Advanced RCC - Camillo Porta
PIVOT-09 Trial: An In-Depth Analysis of Revisiting IL-2 Therapies in Advanced RCC - Nizar Tannir
The Association Between Depth of Response and Clinical Outcomes in the CheckMate 9ER Trial in Advanced Renal Cell Carcinoma - Andrea Apolo
Innovations and Advances in Advanced Kidney Cancer - Toni Choueiri
Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer - CALYPSO Trial Results - Tom Powles
The ORACLE Study: The Efficacy of Combination Systemic Therapies in Patients with Non-Clear Cell Renal Cell Carcinoma - Deepak Kilari
Advancing Therapeutic Approaches in Sarcomatoid Renal Cell Carcinoma: Lessons from CheckMate 214 - Nizar Tannir
Results from a Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma - Hans Hammers
The CANTATA Trial - Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced RCC - Nizar Tannir
CheckMate 9ER: Extended Follow-Up Reveals Long-Term Benefits of Cabozantinib-Nivolumab Combo for Advanced Renal Cell Carcinoma - Toni Choueiri
Predicting Efficacy of Both Nivolumab and of Nivolumab + Ipilimumab in Frontline mccRCC Patients, An Ancillary Analyses from the BIONIKK Randomized Trial - Maxime Meylan
Exploring the PROSPER Study: A Neoadjuvant Approach to Kidney Cancer - Mohamad Allaf
The PROSPER Trial: A Comprehensive Analysis of Neoadjuvant Nivolumab in Renal Cancer - Naomi Haas
Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad Sadeghi
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
Belzutifan Plus Cabozantinib Shows Manageable Safety with Promising Antitumor Activity In Treatment-Naïve Advanced Clear Cell RCC, The LITESPARK-003 Study - Toni K. Choueiri
Triplet Therapy With Cabozantinib, Nivolumab, and Ipilimumab as First-line Treatment in Patients With Advanced Renal Cell Carcinoma, COSMIC 313 - Toni K. Choueiri
Adding Fecal Microbiota Transplantation (FMT) in Combination with Immunotherapy to Treat Renal Cell Carcinoma, The PERFORM Study - Ricardo Fernandes
OMNIVORE - Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
Final Results of TITAN-RCC Trial - Is a Tailored Approach of Nivolumab and Nivolumab/Ipilimumab as Immunotherapeutic Boost Recommended - Marc-Oliver Grimm
Is There Still a Role for Cytoreductive Nephrectomy? Analysis from the CARMENA Trial, Journal Club - Christopher Wallis & Zachary Klaassen
CheckMate 214: A Deep Dive into Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma - David Cella
The First Neoadjuvant Trial Using Combination Immune Checkpoint Inhibitor and VEGF Inhibitor in Patients With Locally Advanced High-Risk RCC (NeoAvAx) – Axel Bex
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
42-Month Follow-up of KEYNOTE-426, Pembrolizumab plus Axitinib First-Line Treatment for Advanced Renal Cell Carcinoma - Thomas Powles
Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, The CLEAR Trial Journal Club - Christopher Wallis & Zachary Klaassen
VEGF Blockade and Combination Therapeutic Options in Advanced Renal Cell Carcinoma - Andrea Apolo
ESMO 2020: CheckMate-9ER Study of Nivolumab Combined With Cabozantinib Vs. Sunitinib in Participants With Previously Untreated mRCC - Toni Choueiri
Safety and Efficacy of CDX-014, an Antibody-drug Conjugate Directed Against T cell Immunoglobulin Mucin-1 in Advanced Renal Cell Carcinoma - Bradley McGregor
Combination Therapies in Metastatic Kidney Cancer - Chung-Han (Joe) Lee
Advanced Renal Cell Carcinoma Clinical Research Outcomes and Clinical Implications from ASCO 2020 - Toni Choueiri
Immunogenomic Characterization of Advanced Clear Cell Renal Cell Carcinoma Treated with PD-1 Blockade - David Braun
OMNIVORE: Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma - Rana McKay
KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma (RCC) - Brian Rini
Frontline Treatment in Advanced Kidney Cancer - Bradley McGregor
Clinical Trials in Non-clear Cell Kidney Cancer - Darren Feldman
Targeted Therapeutic Approaches to Treat Advanced Kidney Cancer - Che-Kai Tsao
The Use of Active Surveillance in Metastatic Kidney Disease - Jaime Landman and Monty Pal
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic RCC Database Consortium - Shaan Dudani
Innovative Research for Advanced Kidney Cancer - David Braun
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
The Landscape of Systemic Therapy for Metastatic Renal Cell Carcinoma - Petros Grivas
Newly Approved Treatment Options for the Management of Metastatic Kidney Cancer- Lauren Harshman and Toni Choueiri
The Dynamic Landscape of mRCC and the PDIGREE Trial - Tian Zhang
Rapidly Evolving Landscape in Metastatic Renal Cell Carcinoma- Rana McKay
Frontline Data from Keynote 426 - Sandy Srinivas
Paradigm Changing Data for Kidney Cancer - Primo Lara
Targeted Therapies with Immunotherapies In Kidney Cancer - Thomas Powles
Atezolizumab and Bevacizumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma - Rana Mckay
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial - Dena Battle
Patient Advocacy and Resources in Kidney Cancer - Dena Battle
Monitoring Treatment Toxicities in Patients with Renal Cell Carcinoma: discussion with Dan George and Tian Zhang
Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang
Systemic Therapy Options for Renal Cell Carcinoma - Monty Pal
The Use of Molecular Profile in Renal Cancer - Martin Voss
ASSET, A Pilot Study Using Exercise Physiology in Advanced Renal Cell Carcinoma - Mike Harrison
A Review of Adjuvant Studies in Advanced Renal Cell Carcinoma - Tian Zhang
CABOSUN Trial Plus an In-depth Discussion of Kidney Cancer Treatments - Toni Choueiri
CARMENA: Practice Changing Strategies for Kidney Cancer